SS Innovations Reports Unregistered Equity Sales

Ticker: SSII · Form: 8-K · Filed: 2025-01-24T00:00:00.000Z

Sentiment: neutral

Topics: unregistered-securities, equity-sale

TL;DR

SS Innovations sold unregistered shares, could mean dilution.

AI Summary

SS Innovations International, Inc. reported on December 4, 2024, regarding unregistered sales of equity securities and other events. The company, formerly known as AVRA Medical Robotics, Inc., is incorporated in Florida and headquartered in Fort Lauderdale. This filing does not contain specific details on the equity sales or other events.

Why It Matters

This filing indicates potential dilution for existing shareholders due to unregistered equity sales, which may not have undergone the usual regulatory scrutiny.

Risk Assessment

Risk Level: medium — Unregistered sales of equity securities can signal financial distress or a need for capital, potentially leading to dilution and increased risk for investors.

Key Players & Entities

FAQ

What type of equity securities were sold?

The filing states 'Unregistered Sales of Equity Securities' but does not specify the type of securities sold.

What was the aggregate purchase price or other consideration for the unregistered equity securities?

The filing does not provide the aggregate purchase price or other consideration for the unregistered equity securities.

Were these securities sold to a single purchaser or a group of purchasers?

The filing does not specify whether the unregistered equity securities were sold to a single purchaser or a group of purchasers.

What was the date of the earliest event reported?

The date of the earliest event reported is December 4, 2024.

What is the company's principal executive office address?

The company's principal executive office is located at 1600 SE 15th Street, #512, Fort Lauderdale, Florida 33316.

Filing Stats: 669 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2025-01-24 08:00:21

Key Financial Figures

Filing Documents

02 Unregistered Sales of

Item 3.02 Unregistered Sales of Equity Securities. The disclosure set forth in Item 8.01 of this Current Report on Form 8-K is incorporated into this item by reference.

01 Other Events

Item 8.01 Other Events. Dr. Sudhir Srivastava, our Chairman and Chief Executive Officer, through his Bahamian holding company, Sushruta Pvt Ltd. (" Sushruta "), has provided the Company with $2.0 million in financing on December 4, 2024, $5.0 million in financing on January 3, 2025 and an additional $10.0 million in financing on January 20, 2025. Dr. Srivastava has also advised the Company that he intends to provide an undetermined amount of additional financing to support the Company's financial needs for capacity expansion and increased working capital requirements as it expands its business during 2025. Each tranche of financing provided by Dr. Srivastava is evidenced by a one-year convertible promissory note (collectively, the " One-Year Notes "). The One-Year Notes bear interest at the rate of seven percent (7%) per annum, which accrues and is due at maturity. The One-Year Notes are convertible at the option of the holder at a conversion price of $1.38 per share at maturity, or upon the earlier of completion of a Qualified Sale (as defined in the One-Year Notes). The conversion price is subject to adjustment for stock splits, stock dividends and similar recapitalization events. The One-Year Notes were issued in accordance with the exemption from registration afforded by Section 4(a)(2) of and Rule 506(b) of Regulation D under the Securities Act of 1933, as amended, as the Company was provided with appropriate representations as to Sushruta's investment intent and its status as an " accredited investor " as defined in Rule 501(a) of Regulation D. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 24, 2025 SS INNOVATIONS INTERNATIONAL, INC. By: /s/ Sudhir Srivastava Sudhir Srivastava, M.D. Chairman and Chief Executive Officer 2

View on Read The Filing